Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

EuroPCR 2024 | Specific Intracoronary Tests Combined with Angiography for Diagnosing Patients with Chronic Coronary Syndrome: The AID-ANGIO Study

Invasive coronary angiography (ICA) has become the gold standard for the assessment of patients with chronic coronary syndrome (CCS) for obstructive coronary artery disease. However, its ability to detect this condition is limited and it does not detect non-obstructive myocardial ischemia, which can be overlooked.

EuroPCR 2024

To address these limitations, a prospective, observational, multicenter study was conducted to assess the diagnostic performance of advanced invasive diagnosis (AID), which included measuring coronary flow reserve (CFR) and microvascular resistance, and the acetylcholine test, to identify both obstructive and non-obstructive causes of myocardial ischemia in patients with CCS.

The primary endpoint (PEP) of the study was to determine the proportion of patients whose cause of myocardial ischemia was identified using ICA alone compared with ICA + AID.

As a secondary endpoint (SEP), the study assessed the proportion of patients in whom ischemia and non-obstructive coronary artery disease (INOCA) was identified, and the proportion of cases in which AID facilitated the modification of the initial therapeutic plan.

Read also: EuroPCR 2024 | Influence and Effect of CAD Physiopathological Patterns in the Safety and Efficacy of PCI.

The study included 317 patients; most of them were men with an average age of 66 years. Most experienced angina symptoms and around 60% had positive non-invasive ischemia tests. There were complications in a low percentage of cases, mainly related to iatrogenic dissection (0.6%) and ventricular arrhythmias (0.3%), with no events of death or myocardial infarction.

Results showed that ICA alone identified the cause of ischemia in only 32% of patients, while AID identified it in 84% of cases, a significant increase in diagnostic performance compared to ICA alone (p <0.001). Additionally, AID identified a 45-% prevalence of INOCA, and only 16% of all patients undergoing ICA showed no abnormalities. AID also resulted in a change in the initial therapeutic plan in nearly 60% of cases.

Conclusion

In conclusion, AID proved to be a safe and effective strategy for the identification of the causes of myocardial ischemia in more than 80% of patients with CCS, leading to changes in the initial therapeutic plan in most cases.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: Combining angiography and pre-specified intracoronary testing in patients with chronic coronary syndromes: the AID-ANGIO study.

Reference: Adrian Jeronimo et al.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...